|  |  |
| --- | --- |
| **Final Report**  | **RESEARCH GRANTS** |

|  |  |
| --- | --- |
| **Date of report submission** (date format: yyyy-mm-dd) |  |
| **Investigator / Grantee Name** |  |
| **Institution** |  |
| **Project title** |  |
| **Project ID** |  |
| **Research Type** (select all that apply) | [ ] **Foundational/basic research** [ ] **Clinical research** [ ] **Clinical trial**[ ] **Translational research**[ ] **Health services research**[ ] **Social, cultural, environmental, and population health**[ ] **Other: \_\_\_\_\_\_\_\_\_\_\_\_\_\_** |
| **Project start date:**(date format: yyyy-mm-dd) |  |
| **Anticipated project end date:**(date format: yyyy-mm-dd) |  |
| **Period covered by the report**(date format: from yyyy-mm-dd to yyyy-mm-dd) |  |

**INSTRUCTIONS:**

Please use this form to describe the primary outcomes of your research funded by this MS Canada grant**.**

Reports should be submitted within **30 days of the end of the grant** via ProposalCentral. The report should be uploaded to the “Final Report” item under Deliverables on your ProposalCentral account. You will also receive an email notification from ProposalCentral to submit before the deadline.

For any questions or concerns, please contact msresearchgrants@mscanada.ca.

1. **PROJECT SUMMARY FOR PUBLIC USE** (Limit: 1 page maximum)

**MS Canada is interested in the patient-focused impact for this section of the report**. **Please note that information in this section may be used in communication materials that will be distributed to people affected by MS, donors, general public (e.g., website) and other key stakeholders.**

People affected by MS are interested in understanding progress in ongoing research funded by MS Canada. Communication of research progress ensures accountability of this funding, ongoing engagement with the community, and encourages stakeholders to continue supporting our efforts. Please ensure that the project summary is written in non-technical language and is easy to read. Use short, clear sentences and plain language where possible.

In your project summary, please answer the following:

1. Outline the key goals and objectives of the research project.
2. Describe the potential impact of this research on the MS field and for people living with MS.
3. Briefly describe the research approach/methodology and provide an update on the current status of the project.
4. Summarize up to three (3) of the most significant research outputs (i.e., achievements, results, learnings) from the project. For each output, describe the importance of each finding and how it contributes to the overall goals and objectives of the project.
5. Outline key next steps in the research project.
6. If available, please provide photos, videos, or quotes related to the project (i.e., quotes from participants) for inclusion in donor reports and/or for public use.
7. **OVERALL OUTCOMES OF THE PROJECT** (Limit:  500 words or 1 page maximum)

Describe **all outcomes or findings resulting from this** **project** for the entire duration of the funding term and what impact will this outcome have in the MS field and for people affected by MS? (e.g. major advances in understanding the pathogenesis of multiple sclerosis (MS) or new or enhanced therapies for the disease).

Where applicable please comment on any impact of the research project outcomes on policy (e.g. research cited in public policy documents, advocacy publications, etc.) or in health care practice and program delivery (e.g. research cited in health professional education material, cited in clinical and service guidelines, used in program development, etc.)

1. **SCIENTIFIC ACHIEVEMENTS** (Limit: 2 pages maximum)

The summary should include details of the research conducted with support from MS Canada over the entire funding term. Please outline the main aims of the proposal and provide an update on the status and key results/findings for each aim, and describe future directions. If applicable, figures can be appended and publications can be referenced to support the narrative. All unpublished information should be identified as such and will be treated as confidential. Please note that any major changes to the project must be approved by MS Canada.

|  |  |  |
| --- | --- | --- |
| **PROJECT AIM** | **Status (in progress/completed/not started)** | **Key results/findings** |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |

**Future Directions:**

1. **MANDATORY FOR COLLABORATIVE TEAM GRANTS: CONTRIBUTIONS OF THE TEAM** (Limit: 500 words or 1 page maximum)

Describe how the collaboration between the team members and the sites contribute to the outcomes of the project.

1. **UNDERSTANDING IMPACT**

Please note that information in this section may be used in communication materials that will be distributed to people affected by MS, donors, general public and other key stakeholders.

Please complete the following to include activities that occurred **over** **the entire funding term** and are related to the grant provided by MS Canada.

|  |  |  |
| --- | --- | --- |
| **Type** | **Number** | **List / Description / References** |
| **KNOWLEDGE GENERATION:** |
| **Peer-reviewed publications** (TOTAL) |  |  |
| **Manuscripts submitted/in preparation** |  |  |
| **Non peer-reviewed publications** (TOTAL) |  |  |
| **Open access publications** (both peer-reviewed and non-peer reviewed) |  |  |
| **Citations in non-academic publications** (i.e., in clinical guidelines, educational materials and/or policy briefs/documents) |  |  |
| **ENGAGEMENT ACTIVITIES:** |
| **Presentation(s)** at scientific conference/workshop/ meeting |  |  |
| **Poster(s)** at scientific conference/workshop/meeting |  |  |
| **Presentation(s) to engage non-scientific audiences** (e.g., public educational activities/workshops). For each activity, indicate the type and size (exact or estimated) of audience. |  |  |
| **Other engagement activities** (e.g., membership on advisory committee, national consultation). |  |  |
| **COLLABORATIONS & PARTNERSHIPS:** |
| **New collaboration(s) with other researcher(s).** For each collaborator, indicate name, institution and research area/expertise.  |  |  |
| **New collaboration(s) / partnership(s) with other stakeholders outside of academia** (e.g., industry, people affected by MS, healthcare practitioners, program delivery, policy-makers, etc.). For each collaboration/partnership, indicate name, organization (if applicable), and nature of the collaboration/partnership. If funding is leveraged, list the amount(s) of additional funding. |  |  |
| **PRODUCT DEVELOPMENT:** |
| **Development of a new product** (e.g., tool, research dataset, database, model/product, methodology, etc.).  |  |  |
| **COMMERCIAL ACTIVITIES:** |
| **Pre-clinical development** |  |  |
| **IP filed/granted** |  |  |
| **License/spin-out company.** Specify product name, inventors, company, and dates. |  |  |
| **ADDITIONAL FUNDING:** |
| **Leveraged additional or follow-on funding for this project from other funders** (e.g., grants, fellowships, studentships, infrastructure, equipment, travel, etc.). Please indicate source, funding type, and amount.  |  |  |
| **Total MS-related research funding awarded** from all sources. Please indicate total funding and then list each source, funding type, and amount. |  |  |

1. **TRAINEE SUPPORT AND RESEARCH STAFF ENGAGEMENTS**

Indicate the number and names of the researchers, research staff, and trainees involved in this project over the entire funding term:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **RESEARCH STAFF**  | **Total #** | **Name** | **Institution** | **Role/Title on grant (e.g. PI, co-PI, co-investigator, co-applicant, collaborator, postdoctoral fellow, doctoral, master’s trainee)** |
| **Researchers** **(i.e., PI, co-PI, co-investigator(s), co-applicant(s), collaborator(s))** |  |  |  |  |
| **Research Staff(e.g., research associate, assistant, technician, etc.)** |  |  |  |  |
| **Trainees (e.g., postdoctoral fellow(s), doctoral student(s), master’s student(s), undergraduate(s))** |  |  |  |  |